A phase II study of IMRT with concurrent chemotherapy for esophageal cancer with stage I

A phase II study of IMRT with concurrent chemotherapy for esophageal cancer with stage I - IMRT for esophageal cancer with stage I

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034668

Enrollment

Registered

2018-11-01

Start date

2018-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

superficial esophageal cancer

Interventions

IMRT without elective nodal irradiation 60Gy/30fractions concurrent chemotherapy 5-FU 700mg/m2/day div(24h) day1-4,day29-32 CDDP 70mg/m2/day div(2h) day1,day29

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.histologically proven thoracic esophageal squamous cell carcinoma 2.T1a or T1b with ultrasound endoscopy 3.no lymph node metastases by CT and FDG-PET 4.aged between 20-y and 79-y 5.Performance Status (ECOG):0-2 6.no severe complication 7.no indication or refusal for EMR/ESD or 8.written informed consent

Exclusion criteria

Exclusion criteria: 1.past EMR/ESD history for primary site 2.patient with intramural metastasis 3.past irradiation history for thoracic 4.patient with active malignant tumor 5.patient with severe complication 6.patient with active infection 7.patient with severe interstitial pneumonia 8.patient with ECD or pace maker

Design outcomes

Primary

Measure	Time frame
3-y progression-free survival rate	—

Secondary

Measure	Time frame
Grade 2 or more adverse events and 3-y overall survival rate	—

Countries

Japan

Contacts

Public ContactKeiichi Jingu

Tohoku university graduate school of Medicine Department of Radiuation Oncology

kjingurad@yahoo.co.jp0227177312

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026